Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMO sales

This article was originally published in The Tan Sheet

Executive Summary

Advanced Medical Optics announces Aug. 2 its second-quarter net sales rose 1.7% to $261.4 mil. in part due to the April 2007 acquisition of IntraLase Corp. Recently AMO recalled its MoisturePlus product, which the firm estimates reduced eye care sales by $54 mil. (see next item). The Santa Ana, Calif.-based firm says the reduced sales include $31 mil. in returns and $23 mil. in lost sales. As a result, the company reported negative multipurpose sales of $7.8 mil. The firm also incurred recall-related costs of approximately $27 mil. AMO also says it began shipments this week of a Complete brand multipurpose solution it expects will be available to U.S. and European practitioners in late August (1"The Tan Sheet" July 30, 2007, In Brief). In addition, R&D expense rose 24.8% to $20.7 mil. or approximately 7.9% of sales compared to 6.4% in the 2006 second quarter...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel